对于耐火性转移性结肠直肠癌的Tas-102:一个多中心回顾性队列研究
Matteo Conti1, Elena Bolzacchini1, Giovanna Luchena1
1Oncology Unit, Sant'Anna Hospital, ASST Lariana, 22042 San Fermo della Battaglia, Italy.
Cancers
|July 14, 2023
概括
特里弗鲁里丁/蒂皮拉西尔 (TAS-102) 是有效和安全的预先治疗转移性结直肠癌患者. 老年患者和特殊小组显示出类似的结果和可接受的毒性,证实了TAS-102的存在.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 特里弗鲁里丁/蒂皮拉西尔 (TAS-102) 是一种用于转移性结直肠癌 (mCRC) 的口服化疗.
- 临床试验和现实研究证实了TAS-102的疗效和耐受性.
- 在已发表的文献中,关于老年人和特殊子组的数据有限.
研究的目的:
- 评估TAS-102在预先治疗的mCRC患者中的有效性和安全性.
- 在老年患者 (≥70,≥75,≥80岁) 中评估TAS-102.
- 在特殊的子组中分析TAS-102,包括心脏病患者.
主要方法:
- 对160名连续的mCRC患者进行了回顾性多中心研究.
- TAS-102主要用作第三线治疗 (72%).
- 总生存时间 (OS) 和无进展生存时间 (PFS) 的分析.
主要成果:
- 在总人口中,中位数的OS: 8个月;中位数的PFS: 3个月.
- 在老年人小组中没有观察到与年龄相关的有效性显著下降.
- 在总人口和子组中可接受的毒性概况.
结论:
- 在预先治疗的mCRC患者中,TAS-102证明了有效性和安全性.
- 老年患者和特殊子组具有相似的风险-益处概况.
- 证实了TAS-102在不同患者群体中的实用性.
相关概念视频
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K